114 related articles for article (PubMed ID: 11846617)
1. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Tentori L; Portarena I; Graziani G
Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
[TBL] [Abstract][Full Text] [Related]
2. Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline
Alaklabi S; Roy AM; Chaudhary LN; Gandhi S
Explor Target Antitumor Ther; 2023; 4(6):1301-1309. PubMed ID: 38213539
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis reveals the molecular mechanism of Astragaloside in the treatment of non-small cell lung cancer by inducing apoptosis.
Liu J; Sun Y; Chen W; Deng L; Chen M; Dong J
BMC Complement Med Ther; 2023 Dec; 23(1):461. PubMed ID: 38102661
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the Development of PARP Inhibitors.
Plummer R
Cancer Treat Res; 2023; 186():1-11. PubMed ID: 37978127
[TBL] [Abstract][Full Text] [Related]
5. Counting the cost of public and philanthropic R&D funding: the case of olaparib.
Schmidt L; Sehic O; Wild C
J Pharm Policy Pract; 2022 Aug; 15(1):47. PubMed ID: 35974344
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
7. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Jette NR; Kumar M; Radhamani S; Arthur G; Goutam S; Yip S; Kolinsky M; Williams GJ; Bose P; Lees-Miller SP
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183301
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibition reveals a potential mechanism to promote neuroprotection and treat neuropathic pain.
Komirishetty P; Areti A; Gogoi R; Sistla R; Kumar A
Neural Regen Res; 2016 Oct; 11(10):1545-1548. PubMed ID: 27904474
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
10. Decreased Poly(ADP-Ribose) Polymerase 1 Expression Attenuates Glucose Oxidase-Induced Damage in Rat Cochlear Marginal Strial Cells.
Zhang Y; Yang Y; Xie Z; Zuo W; Jiang H; Zhao X; Sun Y; Kong W
Mol Neurobiol; 2016 Nov; 53(9):5971-5984. PubMed ID: 26526840
[TBL] [Abstract][Full Text] [Related]
11. Standard of care and promising new agents for triple negative metastatic breast cancer.
Mancini P; Angeloni A; Risi E; Orsi E; Mezi S
Cancers (Basel); 2014 Oct; 6(4):2187-223. PubMed ID: 25347122
[TBL] [Abstract][Full Text] [Related]
12. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb infusion as a model to test new agents to treat metastatic melanoma.
Lidsky ME; Speicher PJ; Jiang B; Tsutsui M; Tyler DS
J Surg Oncol; 2014 Mar; 109(4):357-65. PubMed ID: 24522940
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia.
del Moral RM; Gómez-Morales M; Hernández-Cortés P; Aguilar D; Caballero T; Aneiros-Fernández J; Caba-Molina M; Rodríguez-Martínez MD; Peralta A; Galindo-Moreno P; Osuna A; Oliver FJ; del Moral RG; O'Valle F
ScientificWorldJournal; 2013; 2013():486574. PubMed ID: 24319370
[TBL] [Abstract][Full Text] [Related]
15. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
[TBL] [Abstract][Full Text] [Related]
16. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.
Curtin NJ
Br J Pharmacol; 2013 Aug; 169(8):1745-65. PubMed ID: 23682925
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Tang Y; Hamed HA; Poklepovic A; Dai Y; Grant S; Dent P
Mol Pharmacol; 2012 Aug; 82(2):322-32. PubMed ID: 22596349
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Plummer R
Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
[TBL] [Abstract][Full Text] [Related]
20. Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Kim H; Naura AS; Errami Y; Ju J; Boulares AH
Mol Med; 2011; 17(9-10):893-900. PubMed ID: 21607289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
